Codexis, Inc. (CDXS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Codexis, Inc. on October 2, 2024, reporting events that occurred on September 30, 2024. The filing discloses significant changes to the Company's executive leadership team, specifically the appointment of a new Chief Technical Officer and a new Chief Financial Officer.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the restructuring of the Company's senior management team effective September 30, 2024:
- Appointment of Chief Technical Officer: Alison Moore, Ph.D., a former Board member, was appointed as Chief Technical Officer. Concurrently, she resigned from the Board and its committees (Science & Technology Committee and Chair of the Compensation Committee).
- Appointment of Chief Financial Officer: Georgia Erbez was appointed as Chief Financial Officer, replacing Sriram Ryali.
Compensation, Outlook, and Risks
Management commentary is limited to the terms of the new executive employment agreements. No forward-looking guidance, strategic outlook, or specific risk factors were disclosed in this filing.
Compensation Terms for Both Appointees (Dr. Moore and Ms. Erbez):
- Base Salary: $500,000 annually.
- Target Bonus: 50% of annual base salary.
- Equity Grants: Options to purchase 300,000 shares of common stock and 50,000 stock-settled restricted stock units (RSUs).
- Equity Vesting:
- Options: 25% on the first anniversary of commencement, with the remainder vesting monthly (1/48th) thereafter.
- RSUs: Vest in substantially equal installments over three years.
- Severance Provisions:
- Standard Termination: 12 months of base salary and 12 months of healthcare coverage if terminated without cause or resignation for good reason (outside the change of control window).
- Change of Control Window: 18 months of base salary, 18 months of healthcare, and full accelerated vesting of equity if termination occurs within 90 days prior to or one year following a change of control.
Investor Verification Checklist
- Verify the impact of Dr. Moore's resignation from the Board on the composition of the Science & Technology and Compensation Committees.
- Confirm the total dilution impact of the 350,000 equity units (options and RSUs) granted to each new executive.
- Review the Company's cash burn rate to assess the immediate impact of the combined $1,000,000 in new annual base salaries.
- Check for any subsequent filings regarding the departure of the former CFO, Sriram Ryali, to understand the transition timeline.